Draft:Compact Sequencing
molecular diagnostic technology
From Wikipedia, the free encyclopedia
"Compact Sequencing" is a rapid molecular diagnostic method based on a cylindrical microarray, the so called “hybcell”.[1]
 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 3,824 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
The method combines PCR (Polymerase chain reaction) with array-based detection to enable the parallel analysis of multiple genetic targets. These may include pathogenic microorganisms, antimicrobial resistance markers, or genetic mutations relevant to infectious diseases and cancer. [1][2]
The workflow typically involves amplification of target nucleic acids by PCR, during which the products are fluorescently labelled. The labelled amplicons are then applied to the hybcell, where complementary sequences hybridize to immobilized probes on the array surface. Hybridization is followed by enzymatic processing and washing steps to increase specificity, and fluorescence signals are detected and analysed computationally to determine the presence of specific targets.[1]
The cylindrical design of the hybcell distinguishes it from conventional planar microarrays. This geometry facilitates controlled distribution of reagents and temperature and allows integration into automated processing systems. The technology has been applied in molecular diagnostics, including the detection of pathogens and clinically relevant genetic markers, for example in infectious disease diagnostics such as sepsis and bloodstream infections.[1][3]
History and Development
The hybcell is the world's first cylindrical microarray. Dr. Bernhard Ronacher, the inventor of the compact sequencing technology, headed the molecular diagnostics laboratory of Lambda GmbH, which started out during the years 2000 to 2002. There he established the DNA array technology. In 2001 the first Austrian biochip, ParoCheck, was filed for patent. [4]
The underlying technology for compact sequencing has been described in patent applications, including a device for thermally regulating a rotationally symmetrical container used for nucleic acid detection.[2] Ever since, the technology has found application in diverse fields including Oncology, Microbiology and Sepsis, with a growing global impact in hospitals and diagnostic laboratories.[3] The technology has also been described in peer-reviewed publications.[1][3]
The technology has been commercialised by Cube Dx, which develops diagnostic assays based on the hybcell platform. In 2023, the invention received the Houska Prize, winning first place in the Research & Development category in Austria.[5]
Technology and Method
Compact sequencing is a molecular diagnostic method that combines PCR amplification with array-based detection. Target nucleic acids, including DNA or RNA (e.g., bacterial, viral, or fungal pathogens), are amplified and fluorescently labelled. The labelled amplicons are then applied to the hybcell, a cylindrical microarray containing immobilized probes corresponding to specific target sequences. Hybridization is followed by enzymatic reactions and stringent washing steps to increase specificity. Fluorescence scanning produces a signal pattern reflecting the presence of target sequences in the original sample.[1][3]
Hybcell
The hybcell consists of a core, tube, lid, and handling tray. Up to 2,000 biomolecule spots, including DNA, proteins, or small molecules, are printed on the coated surface of the hybcell core. During analysis, the core rotates within the sample-containing tube to facilitate uniform contact with the hybridization solution, after which fluorescence detection provides data for downstream analysis.[1]
Hyborg
The Hyborg device automates hybcell processing, including hybridization, washing, and fluorescence scanning. It is capable of processing multiple hybcells per run, about 15 minutes per hybcell, and generates digital output for analysis. Software associated with the device interprets fluorescence patterns to provide qualitative information on the presence of target sequences, including species identification or detection of specific point mutations. [1][3]
Analysis Method
Hybcells can be configured for DNA, protein, or small-molecule detection. Most applications require analysis on DNA-level, such as for example the detection of pathogens or drug-resistances. For nucleic acid targets, extracted DNA or RNA is amplified using PCR or reverse-transcription PCR. Fluorescently labelled amplicons are hybridized to complementary probes on the hybcell. Enzymatic extension of bound DNA and subsequent stringent washing allow distinction of sequences differing by a single nucleotide. The resulting fluorescence patterns are analysed computationally to provide qualitative identification of targets, including species-level resolution or detection of single-base variants.[1][3]
Applications
Compact sequencing and the hybcell technology have found application in diverse fields, and are primarily focused on infectious disease diagnostics, such as pneumonia and bloodstream infections. Other applications include the detection of relevant point mutations in SARS CoV-2 spike protein or KRAS mutation testing in cancer diagnosis.[1][4][3]
Beyond human diagnostics, compact sequencing has been adapted for example for wastewater monitoring and epidemiological surveillance.[6]
Relevance in Sepsis
Sepsis is one of the most common diseases and causes of death worldwide.[7] Successful treatment and survival depend heavily on the early identification of causative pathogens.[8] Traditional methods, including pathogen visualization by microscopy and culture-based techniques, typically require at least 24 hours for results. In contrast, rapid molecular assays are increasingly used for timely identification of pathogens.[8][9] As a rapid molecular assay, compact sequencing provides timely qualitative information about the pathogens present in the sample, can thus aid treatment decisions including the administration or de-escalation of antibiotics, antimycotics and other measures.[9][8]
Comparison to Other Methods
Compact sequencing differs from conventional planar microarrays by its cylindrical design and automated processing, facilitating uniform reagent distribution and resulting shorter processing times and higher sensitivity.[1] A study directly comparing the method with state-of-the-art next-generation sequencing methods such as pyrosequencing, Sanger sequencing, and 454 sequencing showed, that compact sequencing is suitable for applications requiring timely qualitative identification of clinically relevant point mutations, as it provides rapid, parallel detection of multiple targets within a panel.[1] However, as a targeted method, compact sequencing is limited in that it does not provide exhaustive sequence information.[1][9]
Specifically in the area of molecular diagnostics, rapid molecular assays are increasingly used to complement blood culture techniques in the diagnosis of infections. These molecular techniques are based on the detection of nucleic acid targets rather than viable organisms which infers a lower sensitivity - as there is no signal amplification by cell growth - but also a reduced bias towards fast-growing organisms.[9] While rapid molecular assays, including compact sequencing, bear the great benefit of timely indication, blood culture remains essential to identify phenotypic characteristics of microorganisms and giving definite information on the presence of viable pathogens.[9][10]